You are here

Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA

Last updated on December 6, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neuropathic Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Clinical diagnosis of neuropathic pain and inclusion according to the current Summary
of Product Characteristics.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- The patients were excluded according to the current Summary of Product
Characteristics.

NCT00843284
Pfizer
Completed
Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA
Assessing the Treatment of Patients With Neuropathic Pain Using LYRICA; A Non Interventional Post-marketing Study (NI-PMS)
A Non-Interventional, Post-Marketing Surveillance (NI-PMS) study whose objectives were to assess the impact of pregabalin on subjects' pain, quality of sleep, and their general wellbeing, as well as the tolerance and safety of pregabalin in subjects with neuropathic pain.
A non-interventional study of patients diagnosed with neuropathic pain administered pregabalin and followed up for 8 weeks
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with neuropathic pain
Neuropathic Pain
Drug: Pregabalin
Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
Patients with neuropathic pain
Intervention: Drug: Pregabalin
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
691
March 2008
March 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of neuropathic pain and inclusion according to the current Summary of Product Characteristics.

Exclusion Criteria:

  • The patients were excluded according to the current Summary of Product Characteristics.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00843284
A0081139
ATLAS
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2009

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now